Quinolinate differentiates between forebrain and cerebellar NMDA receptors

Daniel T Monaghan, J. A. Beaton

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

The potency of N-methyl-D-aspartate (NMDA), ibotenate, L-glutamate and quinolinate for inhibiting [3H]L-glutamate binding to rat brain NMDA receptors was determined by quantitative autoradiography. In contrast to NMDA, ibotenate and L-glutamate, quinolinate more potently displaced binding in forebrain regions than in the cerebellum. Of all drug-region combinations, only quinolinate affinity in the cerebellum was best described by a two-affinity component model (Ki = 24 and 275 μM; 45% high affinity). The cerebellum appears to contain a unique quinolinate-insensitive NMDA receptor subtype.

Original languageEnglish (US)
Pages (from-to)123-125
Number of pages3
JournalEuropean Journal of Pharmacology
Volume194
Issue number1
DOIs
StatePublished - Feb 26 1991

Fingerprint

Quinolinic Acid
Prosencephalon
N-Methyl-D-Aspartate Receptors
Cerebellum
Glutamic Acid
N-Methylaspartate
Drug Combinations
Autoradiography
Brain

Keywords

  • Autoradiography
  • Cerebellum
  • NMDA receptors
  • Quinolinate

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Quinolinate differentiates between forebrain and cerebellar NMDA receptors. / Monaghan, Daniel T; Beaton, J. A.

In: European Journal of Pharmacology, Vol. 194, No. 1, 26.02.1991, p. 123-125.

Research output: Contribution to journalArticle

@article{8d7f8770802b44fb9b570cb98b8eba3f,
title = "Quinolinate differentiates between forebrain and cerebellar NMDA receptors",
abstract = "The potency of N-methyl-D-aspartate (NMDA), ibotenate, L-glutamate and quinolinate for inhibiting [3H]L-glutamate binding to rat brain NMDA receptors was determined by quantitative autoradiography. In contrast to NMDA, ibotenate and L-glutamate, quinolinate more potently displaced binding in forebrain regions than in the cerebellum. Of all drug-region combinations, only quinolinate affinity in the cerebellum was best described by a two-affinity component model (Ki = 24 and 275 μM; 45{\%} high affinity). The cerebellum appears to contain a unique quinolinate-insensitive NMDA receptor subtype.",
keywords = "Autoradiography, Cerebellum, NMDA receptors, Quinolinate",
author = "Monaghan, {Daniel T} and Beaton, {J. A.}",
year = "1991",
month = "2",
day = "26",
doi = "10.1016/0014-2999(91)90134-C",
language = "English (US)",
volume = "194",
pages = "123--125",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Quinolinate differentiates between forebrain and cerebellar NMDA receptors

AU - Monaghan, Daniel T

AU - Beaton, J. A.

PY - 1991/2/26

Y1 - 1991/2/26

N2 - The potency of N-methyl-D-aspartate (NMDA), ibotenate, L-glutamate and quinolinate for inhibiting [3H]L-glutamate binding to rat brain NMDA receptors was determined by quantitative autoradiography. In contrast to NMDA, ibotenate and L-glutamate, quinolinate more potently displaced binding in forebrain regions than in the cerebellum. Of all drug-region combinations, only quinolinate affinity in the cerebellum was best described by a two-affinity component model (Ki = 24 and 275 μM; 45% high affinity). The cerebellum appears to contain a unique quinolinate-insensitive NMDA receptor subtype.

AB - The potency of N-methyl-D-aspartate (NMDA), ibotenate, L-glutamate and quinolinate for inhibiting [3H]L-glutamate binding to rat brain NMDA receptors was determined by quantitative autoradiography. In contrast to NMDA, ibotenate and L-glutamate, quinolinate more potently displaced binding in forebrain regions than in the cerebellum. Of all drug-region combinations, only quinolinate affinity in the cerebellum was best described by a two-affinity component model (Ki = 24 and 275 μM; 45% high affinity). The cerebellum appears to contain a unique quinolinate-insensitive NMDA receptor subtype.

KW - Autoradiography

KW - Cerebellum

KW - NMDA receptors

KW - Quinolinate

UR - http://www.scopus.com/inward/record.url?scp=0026021809&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026021809&partnerID=8YFLogxK

U2 - 10.1016/0014-2999(91)90134-C

DO - 10.1016/0014-2999(91)90134-C

M3 - Article

VL - 194

SP - 123

EP - 125

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1

ER -